Trial Profile
A phase II randomized, controlled, open-labeled (dose-blinded) dose finding study of the safety and efficacy of I-040202 in the treatment of patients with acute open tibial shaft fractures
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 01 Aug 2022
Price :
$35
*
At a glance
- Drugs KUR-113 (Primary)
- Indications Fracture
- Focus First in man; Therapeutic Use
- Sponsors Kuros Biosurgery
- 20 Jan 2022 According to Kuros Biosciences media release, data of this study published in peer-reviewed Journal of Bone and Joint Surgery
- 20 Jan 2022 Results published in the Kuros Biosciences Media Release
- 20 Jan 2016 Primary endpoint 'Proportion of patients healed 6 months after the surgery' has been met, according to a Kuros Biosciences media release.